StreetAlpha.app
Home › Stocks › RXRX

Recursion Pharmaceuticals, Inc. (RXRX)

Healthcare
$2.72
▼ −6.53%
LAST CLOSE · NOV 17

Recursion is a Salt Lake City biotech company that uses AI to find and develop medicines for cancer and rare diseases. It last closed at $2.72 on Nov 17, down 6.53% on the day. The average 12-month price target from 2 analysts is $7.50 (+175.7% from the last close), with a high of $8.00 and a low of $7.00. In the past 30 days there were 8 dark pool prints totaling $1.6M, the largest $598K.

AI Auto Pilots
Is RXRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$68.2M
+56.2% vs a year ago
Net income
−$475.7M
−697.1% margin
EPS (diluted)
−$0.86
Free cash flow
−$312.5M
−458.0% margin
Valuation
Market cap
$1.7B
622.8M shares
P/E
–
No P/E while losing money
Price to sales
24.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$549.9M
At Sep 30
Shareholder equity
$905.8M
Shares outstanding
622.8M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.2M$10.2MFY2021FY2022: $39.8M$39.8MFY2022FY2023: $44.6M$44.6MFY2023FY2024: $58.8M$58.8MFY2024FY2025: $74.7M$74.7MFY2025

From RXRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated RXRX in the past 90 days, not enough for a consensus
Average 12-month target
$7.50
▲ 175.7% upside

Based on 2 analysts who set a price target on RXRX in the past 90 days. The average target is $7.50, with a high of $8.00 and a low of $7.00, compared with the last close of $2.72.

$2$4$6$8PAST 108 TRADING DAYS12-MONTH TARGETSHIGH $8AVG $7.50LOW $7May 22LAST CLOSE+12 MO$2$4$6$8PAST 108 DAYSTARGETSHIGH $8AVG $7.50LOW $7May 22LAST CLOSE+12 MO
Highest target$8.00
Average target$7.50
Lowest target$7.00
Latest rating changes
JP MorganMaintained
Nov 16Buy$7
Leerink PartnersMaintained
Sep 25Hold$8
DateFirmActionRatingPrice target
Nov 16JP MorganMaintainedBuy$7
Sep 25Leerink PartnersMaintainedHold$8
Loading…

Technical Analysis

RXRX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 34% below its 20 day and 38% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the 52 week low at $2.50, and the nearest resistance the Pivot R1 at $2.94.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 12.5%/day
Key levels
$5.2452 week high+92.6%
$3.7550 day average+37.9%
$3.6420 day average+33.8%
$3.54100 day average+30.1%
$3.46200 day average+27.2%
$3.13Swing high (Jul 27)+15.1%
$2.94Pivot R1+8.1%
$2.72Pivot+0.0%
$2.72Last close
$2.5052 week low−8.1%
$2.50Pivot S1−8.1%
Indicators
RSI (14)33.34Weak, oversold below 30Neutral
MACD-0.21Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)22.5Weak trend
Williams %R-89.0Oversold below −80, overbought above −20Oversold
CCI (20)-228.0Oversold below −100, overbought above 100Oversold
Rate of change−26.1%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 12.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RXRX

What happened before

See how RXRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RXRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RXRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RXRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
8
Notional
$1.6M
Largest print
$598K
Loading…

RXRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲177 buying vs 153 selling
  • ▲Held by funds +4.1 pts
  • ●Funds holding +2
  • ▲Superinvestors: 5 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding352350+0.6%
In funds' top 10330.0%
Held by funds62.3%58.2%+4.1 pts
New / increased58 / 11948 / 131−1.1%
Reduced / sold out98 / 5599 / 40+10.1%
Put/call ratio1.351.51−10.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RXRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RXRX is in one of them and how their past RXRX trades turned out.

RXRX in the AI portfolios
Loading…

RXRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RXRX in an article yet. Here's the latest on the wider market.

About Recursion Pharmaceuticals

Recursion is a biotechnology company based in Salt Lake City, Utah, that uses artificial intelligence to discover and develop medicines. Its work centers on the Recursion Operating System, a platform that combines biological data, computational molecule design and clinical trial planning. The company develops its own drug candidates, mainly for cancer and rare diseases, and partners with drugmakers such as Roche, Genentech and Sanofi on discovery programs. Its medicines are aimed at patients with serious diseases that have limited treatment options.

Headquarters
Salt Lake City, UT